INmune Bio Inc expected to post a loss of 54 cents a share - Earnings Preview

Inmune Bio

24/03/2025 20:14

INmune Bio Inc INMB.OQ INMB.O is expected to show a fall in quarterly revenue when it reports  results on March 27 for the period ending December 31 2024

​LSEG's mean analyst estimate for INmune Bio Inc is for a loss of 54 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for INmune Bio Inc is $23.00​, above​ its last closing price of $8.12. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.48
-0.50
-0.60
Missed
-20.8
Jun. 30 2024
-0.63
-0.63
-0.50
Beat
20.6
Mar. 31 2024
-0.53
-0.53
-0.61
Missed
-14​
Dec. 31 2023
-0.44
-0.47
Missed
-6.8
​​Sep. 30 2023
-0.39
-0.39
-0.48
Missed
-21.5
Jun. 30 2023
-0.39
-0.40
-0.36
Beat
9.2​
Mar. 31 2023
-0.02
-0.02
-0.36
Missed
-1,700
Dec. 31 2022
-0.47
-0.48
-0.32
Beat
34

This summary was machine generated March 24 at 20:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)